Longevity
The GLP-1 Story: How a Gut Hormone Changed Weight Loss
For most of my career, a patient with severe obesity had two real options, and neither one was great.
The first was the one everyone knows: eat less, move more, try harder. It works for some people, for a while. The second was surgery: remove most of the stomach, or reroute the intestine. That works much better, but it is an operation, and some of its risks last a lifetime.
Then something changed. The breakthrough did not come from a new diet or a new operation. It came from a hormone your own gut has released after every meal you have ever eaten.
This is the story of that hormone: the clue that led scientists to it, why it nearly failed as a medicine, an unlikely rescue from a desert lizard, the trials that proved it works, the newer drug that may soon rival the operating room, and the fine print. It is long. I think it is worth it.
My view, before the evidence
I will tell you up front where I stand: I am a strong believer in these medicines.
I also know that every medicine has side effects, including the most familiar ones. I once cared for a patient with a biceps tendon tear who took naproxen, one of the most common pain medicines there is. He developed a stomach bleed that nearly took his life. Side effects alone are never a reason to avoid a medicine. What matters is the balance of benefit and risk for the person in front of you.
Here is how I put it to patients. If you are otherwise healthy and can lose weight with diet and exercise, you should, and you do not need these medicines. But if you have struggled with severe obesity for years and have not been able to lose the weight, these medicines can be a godsend, because they work. They are prescribed and monitored by a doctor, usually your primary care doctor or a weight-management specialist.
That is my bias. Now let the evidence make its case.
Chapter 1: A clue that made no sense
The first clue turned up in the 1960s, and it puzzled everyone who saw it.
Give a person sugar through a vein, and the pancreas releases insulin. Give the same amount of sugar by mouth, and the pancreas releases far more. Same sugar. Very different response. Somehow the gut was warning the pancreas that food was coming, before the sugar ever reached the blood.
Scientists gave these unknown messengers a name, incretins, long before anyone could say exactly what they were.
In Copenhagen, a Danish physician named Jens Juul Holst saw the same clue from a different angle. Some of his patients had had part of their stomach removed. When they ate, their insulin shot up so high that their blood sugar crashed.1 Food was rushing into the intestine, and the intestine was shouting at the pancreas. Holst set out to find the voice.
Chapter 2: The suspect hiding inside glucagon
Across the Atlantic, in Boston, Dr. Joel Habener's lab was studying the genes of an unlikely animal: the anglerfish. In the early 1980s they found that the gene for glucagon, the hormone that raises blood sugar, carried more than glucagon. Tucked inside it was the code for two related pieces, later named glucagon-like peptides.12
One of them, GLP-1, became the prime suspect. But which version did the body actually use? Chemist Svetlana Mojsov pinned down the short, active form, the one that powerfully releases insulin. Holst's group showed that the gut cuts the gene's product differently than the pancreas does, so the gut makes GLP-1 while the pancreas makes glucagon. Dr. Daniel Drucker helped work out what the hormone does.12
The messenger finally had a name. And almost immediately, it had a problem.
Chapter 3: The two-minute problem
Natural GLP-1 lasts about two minutes in your blood. An enzyme called DPP-4 chops it apart almost as soon as it is released.
That is elegant biology: a quick signal after a meal, gone before the next one. As a medicine, it was useless. To use natural GLP-1 as a treatment, you would need it dripping into a vein around the clock.
For a while, it looked like GLP-1 might stay a fascinating discovery that never helped anyone. The rescue came from a place no one expected.
Chapter 4: The lizard in the Bronx
The Gila monster is a slow, venomous lizard from the deserts of the American Southwest, an animal that can go months between meals.
At the Bronx VA, an endocrinologist named Dr. John Eng was searching animal venoms for new hormones. In 1992 he isolated a peptide from Gila monster venom that he called exendin-4.3 It acted like GLP-1, with one difference that changed everything: DPP-4 could not easily break it apart. It lasted.
The lizard's molecule became exenatide (Byetta), the first GLP-1 medicine, approved for type 2 diabetes in 2005. It was a twice-a-day shot. The door was open.
Chapter 5: Copenhagen again, and an unexpected side effect
Back in Denmark, at Novo Nordisk, Dr. Lotte Bjerre Knudsen led a team that attacked the two-minute problem with chemistry. They attached a fatty acid to the GLP-1 molecule so it would ride through the blood on albumin, a carrier protein, hidden from the enzymes that destroy it. The result was liraglutide, a once-a-day shot. Further refinements produced semaglutide, which lasts long enough to be taken once a week.24
Then came the twist. In diabetes trials, patients on these drugs were losing weight, and not just a little. What looked like a side effect turned out to be the main story.
Liraglutide was approved for weight management in 2014. Semaglutide followed as Wegovy in 2021, and Eli Lilly's tirzepatide as Zepbound in 2023. Daily pills came next: an oral semaglutide approved in December 2025, and orforglipron (Foundayo) in April 2026, a pill with no food or water restrictions.5 In 2024, Habener, Mojsov and Knudsen received the Lasker Award, often called America's Nobel Prize, for this work.4
Chapter 6: What the messenger actually says
Think of GLP-1 as a message your gut sends after a meal: food has arrived; we have enough. The medicines deliver that message louder and longer, to four places.
The brain hears it most. Appetite and reward centers quiet down. People feel full sooner, think about food less, and feel less pull toward high-calorie food. Many describe it as the "food noise" finally going quiet. This, more than anything, is why people lose weight.
The stomach slows down, so a meal keeps you full longer. It is also why nausea is common, and why your anesthesiologist needs to know you take one.
The pancreas releases more insulin, but only when blood sugar is high, which is why these drugs rarely cause low blood sugar on their own.
The heart, blood vessels, kidneys and liver benefit too. Blood pressure, inflammation markers and liver fat improve, and some of that appears to go beyond the weight loss itself.
The newer drugs add more voices. Tirzepatide adds a second gut hormone, GIP. Retatrutide adds a third, glucagon, which raises energy use and burns liver fat. So far, every added voice has meant more weight loss.
Chapter 7: The old way, and why it was so hard
If good programs and willpower were enough, the Look AHEAD trial would have proven it.
More than 5,000 adults with type 2 diabetes got what most people never will: years of dietitians, coaches, exercise sessions and check-ins. It was one of the most intensive lifestyle programs ever studied. They lost 8.6% of their body weight in the first year. By year four, about 5% remained off. When the intervention ended, they were down 6.0%, and the lifestyle group had no fewer heart attacks or strokes than the comparison group.6
That is not a failure of the people in the trial. It is biology. When you lose weight, your body fights back: hunger rises and your body burns fewer calories. Anyone who has dieted seriously has felt that fight.
There is a second, quieter reason exercise alone rarely melts large amounts of weight: the body compensates. When you burn more calories exercising, your body quietly trims energy spent elsewhere. In a large study of more than 1,700 adults, leaner people offset about 30% of the calories they burned in activity, while people with the highest body fat offset about 46%.22 Exercise is still one of the best things you can do for your health. It is just not an efficient way to lose a lot of weight on its own.
The older medicines did not win it either. Orlistat added only a few pounds beyond diet. Phentermine-topiramate, one of the stronger options, reached roughly 10%. Several earlier weight-loss drugs were pulled from the market for safety problems. For people who needed to lose 25% or more of their weight, surgery was the only reliable answer.
Chapter 8: The trials
In 2021, the STEP 1 trial put semaglutide to the test in about 2,000 adults with obesity but without diabetes. After 68 weeks, people on semaglutide had lost an average of 14.9% of their body weight. People on placebo lost 2.4%.7 Medicine had never come close to that before.
A year later, tirzepatide raised the bar. In SURMOUNT-1, people lost 15.0%, 19.5% and 20.9% on the three doses over 72 weeks, versus 3.1% on placebo.8 Then the two drugs met head to head. In SURMOUNT-5, tirzepatide produced 20.2% weight loss and semaglutide 13.7%, about 50 pounds versus 33 pounds.10 Strong
Chapter 9: The question that really mattered
Losing weight is one thing. Cardiologists were waiting on a harder question: would people on these drugs actually have fewer heart attacks and strokes? Many treatments that improve the numbers on a lab report never change what happens to patients.
The SELECT trial was built to answer it. It followed 17,604 adults with heart disease and excess weight, none with diabetes, for an average of about three years. Heart attacks, strokes and deaths from heart disease fell from 8.0% to 6.5%, a 20% relative reduction.9 The weight loss also held steady for four years.9 Remember that Look AHEAD's lifestyle program, for all its effort, did not lower heart events.6 Strong
For me as an orthopedic surgeon, there is another chapter here: joints. Every pound of body weight adds several pounds of load across the knee with each step. In people with knee arthritis and obesity, semaglutide reduced knee pain, and retatrutide's knee arthritis trial reported 28.7% weight loss along with arthritis pain relief.12 For some of my patients, these medicines are the path to a weight at which joint replacement is safer.
Chapter 10: The newcomer: retatrutide
If GLP-1 was the messenger and tirzepatide added a partner, the next question was obvious: what about a third?
Eli Lilly's retatrutide activates three hormone receptors at once: GLP-1, GIP and glucagon. In 2026 the phase 3 results started arriving, and they were striking.
In TRIUMPH-1, 2,339 adults with obesity took retatrutide or placebo for 80 weeks. The average weight loss was 17.6%, 23.7% and 25.0% on the three doses, versus 3.9% on placebo.11 Among people who stayed on the top dose, the average reached 28.3%, and nearly half of them lost at least 30% of their body weight.11 In an extension of people with a BMI of 35 or more, weight loss reached 30.3% at two years.11 In people with diabetes and people with heart disease, the top dose produced about 21% to 23%.12 Those are surgical numbers. Promising
Every good story has a catch, and this one has several. On the top dose, 42% of people had nausea, and 11.3% stopped the drug because of side effects, compared with 4.9% on placebo.13 A new side effect appeared: dysesthesia, an abnormal tingling or burning feeling in the skin, in 12.5% of people on the top dose versus 0.9% on placebo, mostly mild.13 Heart rate rose with the dose. And unlike semaglutide, retatrutide does not yet have a trial showing it prevents heart attacks.
It is not FDA approved. Lilly has said it plans to apply in early 2027.13 Retatrutide sold online today is not a legitimate product, and the FDA says it cannot be compounded.13 If you are tempted, please wait.
Chapter 11: The rival in the operating room
Every story needs a rival, and this one has an old, powerful one: bariatric surgery.
The two most common operations are the sleeve gastrectomy, which removes most of the stomach, and the gastric bypass, which creates a small stomach pouch and reroutes the intestine. Their track record is formidable. In a real-world study of more than 51,000 patients, people who had surgery lost about 24% of their weight at two years. People prescribed a GLP-1 medicine for at least six months lost 4.7%.14 In the long-running Swedish Obese Subjects study, surgery patients lived a median of three years longer than similar patients who did not have surgery, though still 5.5 years less than the general population.15 And it is a one-time treatment. There is no weekly shot to forget, or to stop.
But surgery has its own fine print, and as a surgeon I take it seriously. The risk of dying around the time of the operation is now low, about 0.03% to 0.2%, far lower than twenty years ago.16 Leaks, bleeding and blood clots are uncommon but serious. In studies with ten or more years of follow-up, about 19% of sleeve patients needed a second operation, often a conversion to bypass, frequently for reflux.17 A bypass can bring internal hernias, ulcers where the stomach and intestine are joined, and dumping syndrome.
Then there is the long tail. Nutritional problems are about five times more common after bariatric surgery, and anemia nearly three times more common, even with routine supplements.18 Bypass patients face a higher risk of alcohol problems.18 And every bariatric operation speeds bone turnover, lowers bone density and raises fracture risk.19 I treat a lot of hip fractures. I do not take that lightly.
Chapter 12: Side by side
| Average weight loss | How | Main risks | Status | |
|---|---|---|---|---|
| Lifestyle program | 5% to 9% | Diet, exercise, coaching | Few; regain is common | Always first |
| Semaglutide | About 15% | Weekly shot or daily pill | Stomach side effects, gallbladder, muscle loss, regain if stopped | FDA approved; proven heart benefit |
| Tirzepatide | About 20% to 21% | Weekly shot | Similar to semaglutide | FDA approved |
| Retatrutide | About 25% to 28% | Weekly shot | More stomach side effects, skin tingling, faster heart rate; long-term data limited | Not approved; filing planned for 2027 |
| Bariatric surgery | About 25% to 30% in the first years, less over decades | One operation | Surgical complications, reoperation, lifelong vitamin needs, bone loss | Long-term data; longer life shown |
Here is what the numbers mean. In trials, the newest medicines now reach the range once reserved for surgery. In real life, they do less, mostly because many people stop taking them: in that large real-world study, the researchers noted that as many as 70% of patients may stop GLP-1 treatment within a year.14 Surgery's advantage is that it keeps working without a weekly decision. The medicines' advantage is that they avoid an operation, can be adjusted or stopped, and have proven heart benefit. For some people, the answer is both: surgery first, and a medicine later if the weight starts to return.
Chapter 13: The fine print
The stomach. Nausea, diarrhea, vomiting and constipation are the most common side effects, especially as the dose goes up, and they usually fade. In STEP 1, 4.5% of people stopped semaglutide because of them, versus 0.8% on placebo.7
Muscle. This is the one I care about most. In trials, lean mass made up 25% to 39% of the weight lost: about 35% with semaglutide and 25% with tirzepatide, similar to weight loss from dieting.20 Lean mass is not all muscle, but muscle is what keeps you strong, steady on your feet and out of my operating room. That is why I tell every patient on these drugs the same thing: eat enough protein and lift weights. See Exercise Is the Treatment.
How to protect it. Two things help most: strength training and enough protein. Protein needs rise with age, and European experts recommend that healthy older adults eat at least 1.0 to 1.2 grams per kilogram of body weight a day, more if they are ill.23 On a GLP-1 medicine, when appetite is small, reaching that takes planning. The size of the calorie deficit matters too: in a pooled analysis of training studies, the bigger the deficit, the less muscle people gained from lifting, and a deficit of about 500 calories a day was predicted to erase those gains entirely.24 These medicines can create far larger deficits than that. Lifting and protein are what tilt the weight you lose toward fat instead of muscle. For how I think about protein, see my diet page.
The rebound. Obesity is a chronic disease, and these medicines treat it; they do not cure it. One year after people in STEP 1 stopped semaglutide, they had regained two-thirds of the weight they had lost, and their blood pressure and other gains faded too.21 For most people, these are long-term medicines.
The rest. Gallstones are more common with rapid weight loss, and pancreatitis is rare. Because these drugs caused thyroid tumors in rodents, they are not used in people with a personal or family history of medullary thyroid cancer or MEN2. Before any surgery or procedure, tell your surgeon and anesthesiologist, because a slow stomach matters under anesthesia. Insurance coverage is still uneven, although pills and manufacturer programs have brought some prices down. And some people now take tiny "microdoses" for longevity or inflammation, without trying to lose weight. That has not been studied. Speculative
The verdict
For decades, people with severe obesity were told to try harder, and the results were modest. A hormone first noticed through a clue nobody could explain, which nearly failed because it vanished in two minutes and was rescued by a desert lizard, has changed that.
GLP-1 medicines produce weight loss that used to require surgery. They lower heart attacks and strokes. The next generation may close the gap with the operating room entirely. They are not free of side effects, they work only as long as you take them, and they need to be paired with protein and strength training to protect your muscle. Bariatric surgery remains the most durable single option, with risks of its own.
The right choice depends on the person. It is a conversation worth having with your doctor.
See also: peptides, exercise and the longevity overview.
References
The scientists behind GLP-1: Holst, Habener, Mojsov and Drucker. TIME. 2024.
Ardehali H. Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen awarded Lasker prize for pioneering work on GLP-1. J Clin Invest. 2024.
Diabetes drug from Gila monster venom. U.S. Department of Veterans Affairs. 2019.
GLP-1-based therapy for obesity. Lasker Foundation. 2024.
FDA approves Lilly's oral GLP-1 orforglipron for obesity. AJMC. April 2026.
Pi-Sunyer X. The Look AHEAD trial: a review and discussion of its outcomes. 2014.
Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021.
Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022.
Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT). American College of Cardiology summary; Ryan DH et al. Long-term weight loss effects of semaglutide in the SELECT trial. Nat Med. 2024.
Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.
Retatrutide achieves up to 30.3% average weight loss in phase 3 TRIUMPH-1 trial. AJMC. 2026; The Pharmaceutical Journal. 2026.
Retatrutide delivers up to 22.6% weight loss in two new phase III trials. Pharmaceutical Executive. 2026; TRIUMPH trial tracker.
What pharmacists need to know about retatrutide's TRIUMPH-1 phase 3 results. Pharmacy Times. 2026; Retatrutide TRIUMPH-1 safety and filing plan. 2026.
Head-to-head study shows bariatric surgery superior to GLP-1 drugs for weight loss. ASMBS 2025 (NYU Langone); EurekAlert summary.
Carlsson LMS et al. Life expectancy after bariatric surgery in the Swedish Obese Subjects study. N Engl J Med. 2020.
Arterburn DE et al. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020.
Long-term results of laparoscopic sleeve gastrectomy: a review of studies reporting 10+ years outcomes. Obes Surg. 2023.
Holmberg D, Lagergren J. What do we know about long-term effects of bariatric surgery? Br J Surg. 2022.
Medical management of patients after bariatric surgery. Endotext.
Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022.
Careau V, Halsey LG, Pontzer H, et al. Energy compensation and adiposity in humans. Curr Biol. 2021.
Deutz NEP, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr. 2014.
Murphy C, Koehler K. Energy deficiency impairs resistance training gains in lean mass but not strength: a meta-analysis and meta-regression. Scand J Med Sci Sports. 2022.
General education, not medical advice. GLP-1 medicines are prescription drugs; talk with your doctor about whether one is right for you. Retatrutide is investigational and not FDA approved.